NASDAQ$OM

Outset Medical Inc · Q3 2025 earnings

Q3 2025 earnings · · After market close · Investor relations

Briefing

Outset Medical reported Q3 2025, revenue of $29.4M, a net loss of $17.8M, diluted EPS of $-1.00.

For Q3 2025, Outset Medical reported revenue of $29.4M, a net loss of $17.8M, diluted EPS of $-1.00. Management discusses operating trends, liquidity, and strategic priorities as disclosed in the quarterly filing.

  • Revenue $29.4M.
  • Net loss $17.8M.
  • Diluted EPS $-1.00.

Headline financials

Total Revenue

$29.4M

Previous: $28.7M+2.7%
EPS (adj)

-$1.00

Previous: -$0.55-81.8%
Recurring Revenue

$20M

Previous: $18M+11.1%
Gross Margin

25.4%

Previous: 20.1%+26.4%
Non-GAAP Gross Margin

26.5%

Previous: 21.0%+26.2%
Non-GAAP Net Loss

$18.5M

Previous: $21M-11.9%
Capital Expenditures

-$575K

Previous: -$869K+33.8%
Net Income

-$17.8M

Previous: -$27.9M+36.2%
Operating Income

-$22.5M

Previous: -$23.8M+5.6%
Gross Profit

$9.2M

Previous: $9.82M-6.3%

Revenue & EPS history

Outset Medical · Revenue · Quarterly

$29.4M

Q3 2025+2.7%vs Q3 2024
Beat estimate in 7 of 15 quarters(47%)
ActualEstimate

Revenue by segment

Outset Medical · $30.4M total across 2 segments · Q3 2023

  • Product Revenue
    $23.5M
  • Service and Other Revenue
    $6.83M

Forward guidance

Management discusses Outset Medical's outlook, capital deployment, and key risks as disclosed in the earnings materials and periodic report.

Tailwinds

  • Outset Medical cited progress on strategic priorities in the quarterly filing.
  • Liquidity and balance sheet support continued operations and investment.

Headwinds

  • GAAP profitability remained under pressure in the reported quarter.
  • Macro, competitive, and regulatory factors may affect near-term results.
  • R&D, credit, or project timing can create quarter-to-quarter volatility.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

-2.7%

Avg return

Earnings day

-4.8%

Avg return

5 days after

+0.5%

Avg return

30 days after

50%

12 / 24 earnings

Positive

+33.5%

Q1 2025

Best reaction

-69.6%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.2%-17.1%-2.3%
Q4 2025-16.3%-28.4%-28.3%
Q3 2025-48.6%-61.2%-64.5%
Q1 2025+33.5%+46.8%+78.3%
Q4 2024+2.1%-13.0%-28.7%
Q3 2024+23.7%+36.0%+91.4%
Q2 2024-69.6%-75.0%-86.1%
Q1 2024-13.7%-18.2%+18.7%
Q4 2023+1.8%+9.3%-40.6%
Q3 2023-13.6%-13.8%+33.7%
Q2 2023-14.6%-17.5%-31.8%
Q1 2023+8.3%+3.4%+15.4%
Q4 2022-6.5%-10.6%-30.5%
Q3 2022+20.2%+44.2%+82.5%
Q2 2022+21.8%+23.5%+18.4%
Q1 2022-13.2%-38.5%-39.5%
Q4 2021+9.5%+15.9%+22.6%
Q3 2021-0.1%-4.6%-22.9%
Q2 2021-2.5%-9.9%+21.1%
Q1 2020-5.6%-14.4%-16.7%
Q1 2021-9.1%-11.9%-17.6%
Q2 2020+6.0%+0.1%+12.2%
Q4 2020+12.5%+8.9%+18.4%
Q3 2020+5.5%+29.6%+8.4%
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro